300683 Wuhan Hiteck Biological Pharma
- 26.22
- -0.71-2.64%
Wuhan Hiteck Biological Pharma News
CRO concept stocks fluctuated lower. Hongbo Pharmaceutical fell more than 10%, while Haite Biotech, Pharmaceutical Science, Pharmaceutical Kangde, Haofan Biotech, and Medici followed suit.
CRO concept stocks fluctuated lower. Hongbo Pharmaceutical fell more than 10%, while Haite Biotech, Pharmaceutical Science, Pharmaceutical Kangde, Haofan Biotech, and Medici followed suit.
The A-share innovative drug sector rebounded, and Hongbo Pharmaceutical's 20CM rose and stopped
Gelonghui, May 14 | Hongbo Pharmaceutical rose and stopped 20CM, Haite Biotech rose more than 10%, while Pharmaceutical Stone Technology, Chengdu Pioneer, Pharmaceutical Ming Kangde, and Dizhe Pharmaceutical were ahead of the curve. According to reports, according to reports, a recent study from BCG (Boston Consulting) found that the success rate of AI-generated drug molecules in phase I clinical trials was as high as 80%-90%, while the historical average was about 50%. In just under a year, AI has predicted the structural universe of 200 million proteins.
Haite Biotech (300683.SZ): Commercial sales of the product CPT have recently begun
Gelonghui, May 9丨Haite Biotech (300683.SZ) said on the investor interactive platform that the company's product CPT has recently begun commercial sales.
Haite Biotech (300683.SZ): Recently received a total of 15 million yuan in government grants
Gelonghui, May 7 | Haite Biotech (300683.SZ) announced that the company recently received a total of RMB 15 million in government grants related to revenue.
Haite Biotech (300683.SZ) announced first-quarter results with a net loss of 165.455 million yuan, an increase of 1024%
Haite Biotech (300683.SZ) released its report for the first quarter of 2024. The company's revenue was 1.32...
Haite Biotech (300683.SZ) subsidiary HKG-320 injection clinical trial approved
Haite Biotech (300683.SZ) announced that its subsidiary, Wuhan Haite Biotech Innovative Pharmaceutical Research Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HKG-320 injections approved and issued by the State Drug Administration. HKG-320 injection is a potassium ion competitive acid blocker that can reversibly inhibit proton pump secretion function by competing with potassium ions on proton pumps (resting pumps and active pumps). Clinically intended to reduce bleeding after endoscopic treatment of upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcers in adults risk.
Express News | Haite Biotech: Subsidiary Receives Drug Clinical Trial Approval Notice
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
Haite Biotech (300683.SZ): Will consider carrying out CPT clinical trials overseas in due course and seek listing
Gelonghui March 20 丨 Some investors asked Haite Biotech (300683.SZ) on the investor interactive platform, “Please ask when the CPT overseas project will begin.” The company replied that the company will consider carrying out CPT overseas clinical trials in due course and seek listing.
Haite Biotech (300683.SZ) recently received a government subsidy of 52.4 million yuan
Haite Biotech (300683.SZ) announced that the company and its wholly-owned subsidiary Hanrui Pharmaceutical (Jingmen) Co., Ltd...
Haite Biotech (300683.SZ): Wu Hongxin and Chen Zongmin are no longer actual controllers of the company
Haite Biotech (300683.SZ) announced that the controlling shareholder of the company, Wuhan Sanjiangyuan Investment and Development Co., Ltd. (abbreviation &...
Haite Biotech (300683.SZ): The number of shareholders of the company as of January 31 was 1,178
On February 6, Gelonghui Biotech (300683.SZ) said on the investor interactive platform that as of January 31, the number of shareholders of the company was 11,978.
Haite Biotech (300683.SZ): Pre-loss of 100 million yuan to 135 million yuan in 2023
Gelonghui, January 29丨Haite Biotech (300683.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 10 million yuan to 135 million yuan, loss of 140,0296 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 121 million yuan to 164 million yuan, loss of 478.518 million yuan for the same period last year; operating income of 53.08 million yuan to 64.16 million yuan after deduction. The main reasons for the changes in the company's 2023 performance are as follows: 1. Original
Haite Biotech (300683.SZ): CPT research on extramedullary tumors is still ongoing
Gelonghui, January 10 | Haite Biotech (300683.SZ) said on the investor interactive platform that CPT research on extramedullary tumors is still ongoing, and the future will be an important part of CPT follow-up research.
Haite Biotech (300683.SZ): The holding subsidiary Yiyuantang has dendrobium wine products
Gelonghui January 5 丨 Haite Biotech (300683.SZ) said on the investor interactive platform that the company's holding subsidiary, Yiyuantang, has dendrobium wine products.
Haite Biotech (300683.SZ): There are currently no traditional Chinese medicine products
Gelonghui January 5 丨 Haite Biotech (300683.SZ) said on the investor interactive platform that the company currently has no traditional Chinese medicine products.
Haite Biotech (300683.SZ): Drug production license changes
Gelonghui, December 19|Haite Biotech (300683.SZ) announced that the company recently obtained the “Pharmaceutical Production License” issued by the Hubei Drug Administration and agreed to the change application for the “Pharmaceutical Production License”. The new license changed the name of the drug, and the rest of the content remained the same. The company's current “Pharmaceutical Production License” changed the injectable recombinant modified human tumor necrosis factor-related apoptosis-inducing ligands within the scope of production to eppriamine for injection, adding production line information for injectable epfamine, ensuring normal production and operation of the drug, and better meeting market demand.
Midday announcement: Xinlian Electronics won the bid of 121 million yuan for the National Grid procurement project
Gelonghui, December 14 | A number of listed companies issued announcements in the afternoon. The details are as follows: 1. Hite Biotech: The company's injectable tedizolamide phosphate has been included in the national health insurance catalogue. 2. Longquan Co., Ltd.: Xinfeng Pipeline, a wholly-owned subsidiary, was identified as the winning candidate for the “BZ Project Lot140wa Non-nuclear Pipeline and Pipeline Accessories” of CGN Engineering Co., Ltd., with a bid price of 71,2032 million yuan. 3. Xinlian Electronics: Identified as the winning bidder for the “State Grid Co., Ltd. in the 88th batch procurement in 2023 (second batch of electric energy meters (including electricity consumption information collection) bidding procurement for marketing projects)”, total
Hite Biotech (300683.SZ): The product injectable tedizolamide phosphate was included in the national medical insurance catalogue
On December 14, Gelonghui (300683.SZ) announced that according to the “Notice on Issuance” (Health Insurance<国家基本医疗保险、工伤保险和生育保险药品目录 (2023 年) > Development [2023] No. 30) issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's injectable tedizolamide phosphate was included for the first time in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)” (hereinafter referred to as the “2023 National Health Insurance Catalogue”). Tedizolamide phosphate is an oxazolidone prodrug antibiotic, in vivo
Haite Biotech (300683.SZ): Joined company Zhongmou Medical is mainly in the field of genetic engineering treatment for ophthalmic diseases
Gelonghui, November 23|Some investors asked Hite Biotech (300683.SZ) on the investor interactive platform, “In addition to Jin Lujie, what indications does the company's participation in Zhongmou Medical's gene therapy use?” The company replied that the company's participation in Zhongmou Medical is mainly in the field of genetic engineering treatment for ophthalmic diseases.
Analysis
Price Target
No Data
